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According to estimates made by the 
International Agency for Research on 
Cancer, the second leading cause 
of cancer deaths worldwide is liver 
cancer (1). Hepatocellular carcinoma 
(HCC) is the most common form of 
l iver cancer, and it represents the 
third most common cause of cancer 
mortality worldwide, with an estimated 
half-million new cases diagnosed each 
year (2). The molecular mechanisms 
mediating carcinogenesis in HCC, 
which have not been fully elucidated, 
represent the final stage of a long-
standing liver disease that usually 
begins with an acute hepatic insult that 
progresses to fibrosis and cirrhosis, 
u l t imately leading to hepatocy te 
transformation (3). Several labora-
tories are actively working to charac-
terize the mechanisms responsible 
for hepatocyte transformation and the 
role of mitochondria in liver tumori-
genesis. In the past decade, somatic 
mitochondrial DNA (mtDNA) mutations 
have been identified in several types 
of cancer (4), including HCC (5,6), and 
these mutations are believed to cause 
mitochondrial dysfunction, increase 
the production of reactive oxygen 
species (ROS), and promote tumor 
growth, contributing to the onset of a 
vicious cycle (7,8). This accounts for 
the renewed interest in mitochondrial 
biology and in methods for studying 
mtDNA damage and mechanisms of 
mtDNA repair.
The most widely used method to 
measure nuclear DNA (nDNA) and 
mtDNA damage in mammalian cells 
is quantitative-PCR (Q-PCR) (9). The 
Q-PCR assay for DNA damage is based 
on the principle that many kinds of DNA 
lesions can slow down or block the 
progression of DNA polymerase during 
PCR amplification (10). Therefore, if 
equal amounts of DNA from differently 
treated samples are Q-PCR-amplified 
under identical conditions, DNA with 
fewer lesions will amplify to a greater 
extent than more damaged DNA. In the 
protocol proposed by Furda et al. (9), 
total DNA isolated from cells or tissue is 
used as the template to measure mtDNA 
damage. As part of their protocol, the 
amplification of a short mitochondrial 
fragment (~100 bp), where the proba-
bility of base damage is very low, is 
used to calculate the relative amount 
of mtDNA copies between dif ferent 
samples and to normalize the lesion 
frequencies calculated from a long (~10 
kb) mitochondrial fragment . However, 
high levels of mtDNA damage could be 
underestimated using this approach 
because the short fragment may also 
contain damaged bases that slow down 
or block the action of the polymerase, 
thereby altering the quantification of the 
mtDNA template. 
To normalize the mtDNA copy 
number between dif ferent samples, 
Ballinger et. al used the ratio of nDNA 
to mtDNA (11). However, this approach 
could also lead to inaccurate results. 
For example, it has been demon-
strated that tumor cells are subjected 
to chromosomal rearrangements that 
in the case of HCC could lead to 
differences of 85% in terms of nDNA 
content with respect to healthy tissues 
(12). Here, we demonstrate that to 
accurately measure the level of mtDNA 
damage in HCC tumor tissue, it is 
necessary to isolate mitochondria and 
use mtDNA as the Q-PCR template, 
thereby avoiding the need to amplify 
a short mtDNA fragment to normalize 
the amount of mtDNA.
Human biopsies derived from a 
tumorous liver mass (HCC) and from 
a non-tumorous (distal) section from 
the same patient were processed as 
previously described (13). Liver tissue 
was immersed in 50 mL ice-cold IBc 
buffer, rinsed 2 times to completely 
remove blood, cut into small pieces, 
and transferred to a Potter-Elvehjem 
tissue grinder. Next, 7 mL IBc buffer 
was added, and the liver was homog-
enized using a Teflon pestle at the 
minimum speed until the suspension 
was homogeneous. This process 
leads to the disruption of liver tissue 
and the lysis of cells. The homogenate 
was then transferred to a 15 mL plastic 
tube and centrifuged at 70 × g for 3 
min at 4°C to separate non-homoge-
nized tissue pieces. The supernatant 
was transferred to a 15 mL Falcon tube 
and centrifuged at 600 × g for 10 min 
at 4°C to pellet intact nuclei that were 
then treated separately. The super-
natant, containing mitochondria, was 
transferred to a 15 mL glass centrifuge 
tube and centrifuged at 7000 × g for 
10 min at 4°C. The supernatant was 
discarded, and the pellet, containing 
mitochondria, was washed with 5 mL 
IBc buffer, centrifuged at 7000 × g for 
10 min at 4°C, and resuspended in 800 
µL IBc buffer; this was the mitochon-
drial fraction (MF). The mitochondria 
were finally washed with IBc buffer 
containing 1 M KCl to el iminate 
cytoplasmic proteins and contaminant 
nDNA (14).
The pellet of nuclei was washed by 
gentle resuspension in T1 solution and 
centrifuged at 600 × g for 10 min at 
4°C. To obtain nuclear protein extract, 
the pellet was lysed in T2 solution, 
incubated on ice for 30 min, and then 
centrifuged at 14,000 × g for 20 min 
to remove cell membranes. The super-
natant was collected as the nuclear 
protein fraction (NF). For isolation of 
nDNA, after washing with T1 solution, 
the pellet was lysed with TRI Reagent, 
and nDNA was isolated as reported in 
the Supplementary Material (Figure 1A).
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For western b lot  ana lys is of 
mitochondrial (MF) and nuclear (NF) 
fractions from human HCC biopsies, 
mitochondrial membrane ATP synthase 
complex V (ATP5A) and l ys ine 
(K)-specif ic demethylase 1A (LSD1) 
were used as the mitochondrial and 
nuclear markers, respectively. Western 
blot analysis confirmed the possi-
bility of isolating the two subcellular 
compartments without apparent cross-
contamination (Figure 1B).
Genomic DNA from HCC samples 
was isolated from nuclei (~200 mg of 
nDNA per 1 g of liver tissue). To purify 
the circular, ~16-kb mtDNA, we used 
a plasmid isolation kit (15). Two milli-
grams of isolated mitochondria were 
used to extract mtDNA from HCC and 
non-tumor tissues (~450 ng of mtDNA 
per 1 g of liver tissue) and quantified 
with PicoGreen reagent (Supple-
mentary Figure S1). Figure 1C shows 
an image of an agarose gel in which 
150 ng of mtDNA from the distal area 
and the HCC tissue of Patient 1 were 
separated, showing the presence of 
a single band of ~16 kb. To confirm 
the integrity of the isolated nDNA and 
the absence of nDNA contamination in 
the mtDNA preparation, we amplified a 
region of the human GAPDH gene by 
RT-PCR. We used 100 ng of nDNA as 
the positive control; 10 pg of mtDNA, 
which corresponds to 10 times the 
number of base pairs of nDNA (consid-
ering the nDNA as a unique molecule); 
and a reaction without template as the 
negative control. The nDNA amplified 
with Cq values of 16.79 and 16.93 for 
the distal and tumor tissues, respec-
tively, while the Cq values of mtDNA 
from the distal and tumor regions were 
31.15 and 29.70, respectively. The 
amplif ication of the negative control 
without template was not detectable. 
We demonstrated that through this 
approach it is possible to purify nuclei 
and mitochondria and also isolate high-
quality mtDNA without contamination 
by nDNA.
In contrast to commonly used 
protocols for the evaluation of DNA 
damage, where the mtDNA is not 
separated from the genomic DNA 
(9), we used mtDNA from tumor and 
distal liver regions isolated from four 
patients to evaluate the levels of DNA 
damage in HCC mitochondria with 
respect to healthy tissue. In Figure 2A, 
the gel image and the quantification of 
relative band intensity for the Q-PCR 
analysis of the sample from Patient 1 
Figure 1. Human liver subcellular fractionation. (A) Work-
flow for subcellular fractionation of liver tissue. (B) Western blot 
analysis of mitochondrial (MF) and nuclear (NF) fractions from 
human liver tissues. Samples were separated by 12% SDS-
PAGE and analyzed by western blotting to evaluate the purity 
of the indicated fractions. ATP synthase complex V (ATP5A) 
and lysine (K)-specific demethylase 1A (LSD1) were used as 
mitochondrial and nuclear markers, respectively. (C) Agarose 
gel electrophoresis analysis of human mtDNA extracted from 
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are shown as an example. To verify the 
quantitative amplification conditions, 
1 reaction containing 50% (0.25 ng) 
of the mtDNA template (0.5 ng) and 
1 reaction without sample (0 ng) were 
compared. To this end, fluorescence 
readings of the Q-PCR reactions were 
quantified in triplicate with PicoGreen 
reagent and then averaged for each 
sample. These raw readings were then 
background-corrected by subtracting 
the blank values (9). The relative amplifi-
cation of the mtDNA was determined 
by calculating the ratio of the fluores-
cence readings obtained for the tumor 
tissue to those of the distal section for 
each patient sample. Relative mtDNA 
damage was then expressed as the 
inverse of this relative amplification of 
the mtDNA long fragment. In all cases, 
the mtDNA purified from mitochondria 
of the tumor tissue amplified with lower 
efficiency, an indication of higher levels 
of damage compared with the mtDNA 
derived from the distal section (P = 
0.019) (Figure 2B).
We next amplified a short fragment 
of 221 bp that is typically used to 
normalize the amount of mtDNA when 
nDNA and mtDNA are not separated 
during extraction. To verify quantitative 
amplification conditions, we examined 
1 reaction containing 50% (0.25 ng) of 
the mtDNA template (0.5 ng) and 1 
reaction containing no sample (0 ng). 
In Figure 2C, the short amplicons of the 
distal and HCC mtDNA of Patient 1 are 
visible, and the band analysis shows 
an unexpected reduction of 38% for 
the HCC amplicon with respect to the 
distal section mtDNA. Next, the Q-PCR 
reactions for the short mtDNA fragment 
from all 4 patients were quantified with 
PicoGreen reagent, confirming the 
presence of high levels of base damage 
in the HCC samples (P = 0.019) (Figure 
2D).
To test the hypothesis that high 
levels of mtDNA damage could affect 
amplif ication of the short amplicon, 
thereby al ter ing quanti f ication of 
mtDNA damage levels, we treated 
HeLa cells with increasing amounts of 
H2O2 for 15 min and then measured 
the levels of mtDNA damage. The 
histogram in Figure 2E shows quanti-
f ication of the long mitochondria 
Q-PCR amplicons normalized or not 
normalized to the short PCR fragment. 
Figure 2. Electrophoresis and quantification of Q-PCR products for compara-
tive mtDNA damage analysis. (A) Representative gel image of the Q-PCR analysis of 
the mtDNA long fragment. mtDNA from hepatocellular carcinoma (HCC) tumor and non-
tumor distal tissues of Patient 1 (Pt. 1) were used as template. Amplicons were separated 
on a 0.8% agarose gel, and the band intensity of each lane was measured. (B) Histogram 
showing the relative mtDNA damage analysis of HCC tumor tissues for all four patients. 
Q-PCR was per formed, and levels of mtDNA damage in HCC samples were calculated in 
respect to non-tumor tissue. (C) Representative gel image of the Q-PCR analysis of the 
short mtDNA fragment. mtDNA from HCC tumor and non-tumor distal tissues of Pt. 1 
was used as template. Fragments were separated on a 2% agarose gel, and the band in-
tensity of each lane was measured. (D) Histogram of the ef f iciency of mtDNA short frag-
ment amplif ication all four patients. (E) Comparison of mtDNA damage analysis of HeLa 
cells treated with H2O2,, with the amount of the long mitochondrial Q-PCR amplicons 
normalized (white bars) or not normalized (gray bars) to the short mtDNA amplicons. 
mtDNA damage was calculated as the inverse of mtDNA long fragment amplif ication. 
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Normalized measurements (white bars) 
show an initial increase in mtDNA 
damage, which reaches its maximum 
after treatment with 400 µM of H2O2 
and unexpectedly does not increase 
with higher concentrations of H2O2. 
In contrast, by not normalizing to the 
short mtDNA amplicon (gray bars), we 
observed a significant concentration-
dependent increase in DNA damage 
(Figure 2E).  The reduced amplification 
efficiency of the short mitochondrial 
PCR fragment in cells treated with 
600 µM or 1 mM H2O2 (Figure 2F) 
reveals a bias in measurement of 
mtDNA base lesions when the sample 
is normalized for the short amplicon. 
These data confirm the hypothesis that 
in samples with a high level of damaged 
bases, such as tumor tissues, a short 
mtDNA amplicon should not be used to 
normalize the amount of mtDNA for the 
calculation of mtDNA damage.
In 2014, the Van Houten group 
published an updated Q-PCR-based 
method for measur ing nDNA and 
mtDNA damage in mammalian cells 
that does not require the isolation of 
mtDNA separately from genomic DNA 
(9). This undoubtedly represents the 
main strength of the assay because 
the labor-intensive step of mitochon-
drial isolation is not needed, and 
it also provides information about 
mtDNA copy number. However, our 
data demonstrate that high levels 
of mtDNA damage may be under-
estimated because damage to DNA 
bases could occur also in the short 
amplicon, thereby altering the quanti-
f ication of the relative mtDNA copy 
number (Figure 2, D –F). The present 
study supports the hypothesis that in 
samples with a high level of damaged 
bases, such as tumor tissues, it is not 
possible to use total DNA for calcu-
lation of mtDNA damage.
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